Friday, July 24, 2020 Daily Archives

Fujifilm to make Warp Speed vaccine for Novavax from NC site

by

With $1.6 billion of US government funds in hand, Novavax has contracted CDMO Fujifilm Diosynth Biotechnologies (FDB) to produce Phase III trial material for its COVID-19 vaccine candidate. Earlier this month, the US government handed Novavax – a firm with no approved products – $1.6 billion to progress the development of its vaccine candidate NVX‑CoV2373 against the novel coronavirus (SARS-CoV-2). Until a $2 billion deal was struck this week with Pfizer/BioNTech, the funding was the largest under the Operation Warp…

July 24, 2020

COVID-19 revenue key to Thermo Fisher’s revenue growth in Q2

by

Thermo Fisher’s revenue increased 10% in the second quarter thanks to $1.3 billion generated by COVID-19 related work. Thermo posted revenue of $6.92 billion, up from $6.32 billion in the comparable quarter last year. Life sciences solutions contributed $2.60 billion – up from $1.71 billion – specialty diagnostics brought in $990 million – up from $940 million – and lab products and services generated $2.79 billion, up from $2.63 billion. In contrast, analytical instrument revenue was $1.05 billion, down from $1.32 billion…

July 24, 2020